Curve matching to predict growth in patients receiving growth hormone therapy: An interpretable & explainable method.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this observational study publication.

The researchers aimed to investigate the validity of curve matching to predict growth in patients with GHD and those born SGA receiving recombinant human growth hormone (r-hGH).

Why It Was Studied

Curve matching may be used to predict growth outcomes using data of patients whose growth curves resemble those of a new patient with growth hormone deficiency (GHD) and those born small for gestational age (SGA).

Standard deviation (SD) was obtained from the observed minus the predicted HSDS (error) based on matched patients within the 'Matching Database'.

Who Took Part

According to the abstract, 3,213 patients were involved.

Selected patients with height standard deviation scores (HSDS) [-4, <-1] and age [3, <16y] at start were included.

What Was Measured

Curve matching may be used to predict growth outcomes using data of patients whose growth curves resemble those of a new patient with growth hormone deficiency (GHD) and those born small for gestational age (SGA).

PubMed files the paper under topics including Human Growth Hormone, Growth Hormone, Ecosystem, Dwarfism, Pituitary, Body Height and Recombinant Proteins.

The authors tagged it with the keywords curve matching, growth disorders, growth hormone deficiency, paediatric, prediction model and small for gestational age.

What This Means in Plain Language

This is an observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 3,213 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2022 (Frontiers in endocrinology), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.